List view / Grid view
19 February 2014 | By Paul Wituschek, Vice President of Sales, Development and Clinical Services, Catalent
Paul Wituschek, Vice President of Sales, Development and Clinical Services, Catalent answers the question: "Other than oncology, for which disease areas do you see Antibody Drug Conjugates (ADC) being used extensively in the future?"
Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) are colloidal systems of interest for the delivery of poorly water-soluble drugs.
Freeman Technology and GEA Pharma Systems have conducted a study to investigate the feasibility of predicting critical quality attributes (CQA) of tablets from intermediate granule properties...
In Issue #6 2013: PAT in-depth focus, Lab Automation, Proteomics, Next Gen Sequencing, Screening in-depth focus, Microbiology...
15 December 2013 | By Christos Georgakis, Department of Chemical and Biological Engineering and Systems Research Institute for Chemical and Biological Processes, Tufts University and Gregory M. Troup, Merck Research Laboratories, Merck & Co., Inc
Process Systems Engineering (PSE) has had a profound impact in the chemical, petroleum and petrochemical industry in the last 30 - 40 years. Even though PSE has already started to make a significant impact on the pharmaceutical industry, there are substantial additional benefits that can be derived. The purpose of…
Read the free digital version of Issue #5 2013 of European Pharmaceutical Review magazine...
Read the free digital version of the August / September edition of European Pharmaceutical Review magazine...
Read the free digital version of the June / July edition of European Pharmaceutical Review magazine...
In this Ingredients In-Depth Focus: Revisiting a mutual recognition agreement approach for GMP inspections to secure the safety of the supply chain of APIs; Solid form diversity of commonly used tableting excipients and its impact...
Inspection of incoming raw materials is an essential step in the pharmaceutical industry to verify that the correct raw material which meets the quality specifications has been received. It will not only help to ensure that the final product is of best quality and minimise wasted time, material costs and…
18 April 2013 | By Pascal Furrer, Pharmacist
Active substances are rarely administered alone. For example, levothyroxine, a synthetic form of the thyroid hormone, indicated in the treatment of hypothyroidism, is administered at a very low dosage, ranging from 15 μg to 200 μg. These very small amounts of powder mean that it is not possible to manufacture…
In this Mass Spectrometry In-Depth Focus: Corticosteroids and mass spectrometry; latest applications using LC/MS; Multi-analyte LC-MS/MS assays for the quantification of endogenous compounds during the development of drugs and companion diagnostics...
25 February 2013 | By Esther P. Black, College of Pharmacy and Markey Cancer Center, University of Kentucky
Cancer treatment faces a conundrum: a growing lack of therapeutics with lasting effects. The low hanging fruit of the medicinal chemistry orchard seems to have been picked, and modification of existing anti-cancer therapeutics has produced only incremental rewards[1]. Thus, both pharmaceutical companies and academic researchers are left searching for new…
21 February 2013 | By Eric Munson, Patrick DeLuca Endowed Professor in Pharmaceutical Technology, Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky
Solid-state NMR spectroscopy (SSNMR) has emerged as an extremely powerful analytical technique for the characterisation of pharmaceuticals[1-5]. Despite its capability, SSNMR is still not used ubiquitously in the pharmaceutical industry. Several factors contribute to this, including cost and analysis time, but two of the major reasons are understanding the full…
18 December 2012 | By D. Lansing Taylor, Director, University of Pittsburgh Drug Discovery Institute and Allegheny Foundation Professor of Computational and Systems Biology, University of Pittsburgh School of Medicine
The pharmaceutical industry has experienced a decade of turbulence driven by the ‘patent cliff’ as major revenue generators are lost to generic status, coupled to the absence of a sustainable pipeline of drug candidates in development that have a good chance of being approved and launched. It is generally agreed…
